cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2021-3011cardiovascular-3011Research ArticleМНЕНИЕ ПРИГЛАШЕННОГО РЕДАКТОРАOPINION OF INVITED EDITORПовышенный уровень сердечного тропонина I, определенного высокочувствительным методом: клиническое значение за пределами оценки тяжести и прогноза острых и хронических заболеванийIncreased level of cardiac troponin I determined by a highly sensitive method: clinical significance beyond the assessment of the severity and prognosis of acute and chronic diseaseshttps://orcid.org/0000-0003-2816-1183ЯвеловИ. С.YavelovI. S.

Доктор медицинских наук, руководитель отдела фундаментальных и клинических проблем тромбоза при неинфекционных заболеваниях.

Москва.

Moscow.

IYavelov@gnicpm.ruНациональный медицинский исследовательский центр терапии и профилактической медицины Минздрава РоссииNational Medical Research Center for Therapy and Preventive Medicine20213107202120530113011Copyright © Явелов И.С., 20212021Явелов И.С.Yavelov I.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/3011

Читайте статью: Шальнова С. А., Драпкина О. М., Концевая А. В., Яровая Е. Б., Куценко В. А., Метельская В. А., Капустина А. В., Баланова Ю. А., Литинская О. А., Покровская М. С. Пилотный проект по изучению ассоциации тропонина I с сердечнососудистыми осложнениями в популяции российского региона в разделе Оригинальные статьи, стр. 185-192.

See: Shalnova S. A., Drapkina O. M., Kontsevaya A. V., Yarovaya E. B., Kutsenko V. A., Metelskaya V. A., Kapustina A. V., Balanova Yu. A., Litinskaya O. A., Pokrovskaya M. S. Pilot project to study the association of troponin I with cardiovascular events in the population of Russian region in Original articles, pp. 185-192.

сердечный тропонин Iвысокочувствительный методпрогнозпопуляцияCardiac troponin Ihighly sensitive methodprognosispopulationReferencesThygesen K, Alpert JS, Jaffe AS, et al.: The Executive Group on behalf of the Joint European Society of Cardiology (ESC)/ American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction. Eur Heart J. 2018;40(3):237-69. doi:10.1093/eurheartj/ehy462.Thygesen K, Alpert JS, Jaffe AS, et al.: The Executive Group on behalf of the Joint European Society of Cardiology (ESC)/ American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction. Eur Heart J. 2018;40(3):237-69. doi:10.1093/eurheartj/ehy462.Januzzi JL, Mahler SA, Christenson RH, et al. Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing. JACC Scientific Expert Panel. JACC. 2019;73(9):1059-77. doi:1016/j.jacc.2018.12.046.Januzzi JL, Mahler SA, Christenson RH, et al. Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing. JACC Scientific Expert Panel. JACC. 2019;73(9):1059-77. doi:1016/j.jacc.2018.12.046.Инструкция по применению. https://www.ifcc.org/media/477656/high-sensitivity-cardiac-troponin-i-and-t-assay-analytical-characteristics-designated-by-manufacturer-v012019.pdfARCHITECT STAT High Sensitive Troponin-I. Instructions for use. (In Russ.) ARCHITECT STAT High Sensitive Troponin-I.Jia X, Sun W, Hoogeveen RC, et al. High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the Atherosclerosis Risk in Communities (ARIC). Study. Circulation. 2019;139(23):2642-53. doi:10.1161/CIRCULATIONAHA.118.038772.Jia X, Sun W, Hoogeveen RC, et al. High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the Atherosclerosis Risk in Communities (ARIC). Study. Circulation. 2019;139(23):2642-53. doi:10.1161/CIRCULATIONAHA.118.038772.Omland T, Pfeffer MA, Solomon SD, et al. Prognostic Value of Cardiac Troponin I Measured with a Highly Sensitive Assay in Patients With Stable Coronary Artery Disease. JACC. 2013;61:1240-9. doi:10.1016/j.jacc.2012.12.026.Omland T, Pfeffer MA, Solomon SD, et al. Prognostic Value of Cardiac Troponin I Measured with a Highly Sensitive Assay in Patients With Stable Coronary Artery Disease. JACC. 2013;61:1240-9. doi:10.1016/j.jacc.2012.12.026.Raber I, McCarthy CP, Januzzi JrJL. A Test in Context: Interpretation of High-Sensitivity Cardiac Troponin Assays in Different Clinical Settings. JACC. 2021;77(10):1357-67. doi:10.1016/j.jacc.2021.01.011.Raber I, McCarthy CP, Januzzi JrJL. A Test in Context: Interpretation of High-Sensitivity Cardiac Troponin Assays in Different Clinical Settings. JACC. 2021;77(10):1357-67. doi:10.1016/j.jacc.2021.01.011.Sigurdardottir FD, Lyngbakken MN, Holmen OL, et al. Relative prognostic value of cardiac troponin I and C-reactive protein in the general population (from the HUNT Study). Am J Cardiol. 2018;121:949-55. doi:10.1016/j.amjcard.2018.01.004.Sigurdardottir FD, Lyngbakken MN, Holmen OL, et al. Relative prognostic value of cardiac troponin I and C-reactive protein in the general population (from the HUNT Study). Am J Cardiol. 2018;121:949-55. doi:10.1016/j.amjcard.2018.01.004.Blankenberg S, Salomaa V, Makarova N, et al. Troponin I and cardiovascular risk prediction in the general population: The BiomarCaRE consortium. Eur Heart J. 2016;37(30):2428-37. doi:10.1093/eurheartj/ehw172.Blankenberg S, Salomaa V, Makarova N, et al. Troponin I and cardiovascular risk prediction in the general population: The BiomarCaRE consortium. Eur Heart J. 2016;37(30):2428-37. doi:10.1093/eurheartj/ehw172.Willeit P, Welsh P, Evans JDW, et al. High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants. JACC. 2017;70:558-68. doi:10.1016/j.jacc.2017.05.062.Willeit P, Welsh P, Evans JDW, et al. High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants. JACC. 2017;70:558-68. doi:10.1016/j.jacc.2017.05.062.Everett BM, Zeller T, Glynn RJ, et al. High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation. 2015;131(21):1851-60. doi:10.1161/CIRCULATIONAHA.114.014522.Everett BM, Zeller T, Glynn RJ, et al. High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation. 2015;131(21):1851-60. doi:10.1161/CIRCULATIONAHA.114.014522.Шальнова С.А., Драпкина О.М., Концевая А. В. и др. Пилотный проект по изучению тропонина I в представительной выборке одного из регионов-участников исследования ЭССЕ-РФ: распределение в популяции и ассоциации с факторами риска. Кардиоваскулярная терапия и профилактика. 2021;20(4):2940. doi:10.15829/1728-8800-2021-2940.Shalnova SA, Drapkina OM, Kontsevaya AV, et al. A pilot project to study troponin I in a representative sample of the region from the ESSE-RF study: distribution among population and associations with risk factors. Cardiovascular Therapy and Prevention. 2021;20(4):2940. (In Russ.)Farmakis D, Mueller C, Apple FS. High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. Eur Heart J. 2020;41(1):4050-6. doi:10.1093/eurheartj/ehaa083.Farmakis D, Mueller C, Apple FS. High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population. Eur Heart J. 2020;41(1):4050-6. doi:10.1093/eurheartj/ehaa083.

The authors declare that there are no conflicts of interest present.